Dhaval Patel, Executive Vice President and Chief Scientific Officer at UCBDhaval Patel, Executive Vice President and Chief Scientific Officer at UCB

Brussels, Belgium — UCB, a global biopharmaceutical company focused on the discovery and development of innovative medicines, made a strategic investment in IMIDomics, a company focusing on developing medicines for immune-mediated inflammatory diseases.

The investment aims to support innovative solutions for patients with these conditions and potentially lead to collaborative research efforts between the two companies.

 

Update: Airbus Puts Up Zu As Board Member

Dhaval Patel, Executive Vice President and Chief Scientific Officer at UCB said:

“This investment represents more than just financial support. It underscores our belief in IMIDomics’ potential and our commitment to fostering their pioneering efforts in the field of immune-mediated inflammatory diseases. We see this as an opportunity to contribute to enhancing patient care standards, and to collaboratively support the progression of medical innovation.”

By Lisa Luckas

Lisa Luckas is a Sr. Business News Editor at Nobot.News.

Leave a Reply

Your email address will not be published. Required fields are marked *

GDPR Cookie Consent with Real Cookie Banner